CDT Equity Inc. (CDT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 17 wire items for CDT, including 10 SEC filings, 3 press releases and news items and 3 insider trades. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Net income, TTM
- -$37.15M
- Cash
- $747.0K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks61+63%
2026-05-172026-11-08
Mix3890d
- SEC Filings22(58%)
- Other10(26%)
- Insider4(11%)
- Leadership1(3%)
- 13D/G1(3%)
Activity · 52 weeks10569 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- SECCDT Equity Inc. filed SEC Form 8-K: Other Events8-K - CDT Equity Inc. (0001896212) (Filer)
- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by CDT Equity Inc.SCHEDULE 13D/A - CDT Equity Inc. (0001896212) (Subject)
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- SECCDT Equity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded PeptidesNAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for compounded peptides, which the Company believes is supportive of its strategic investment in Pep’d Inc., a U.S.-based peptide and telehealth company. The U.S. Department of Health and Human Services ("HHS") has announced an interim enforcement discretion policy covering six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 while the U.S. Food and Drug Administration ("FDA") continues the rulemaking process concerning the Section 503A Bulks List. Under
- SECSEC Form DEF 14A filed by CDT Equity Inc.DEF 14A - CDT Equity Inc. (0001896212) (Filer)
- INSIDERSEC Form 4 filed by CDT Equity Inc.4 - CDT Equity Inc. (0001896212) (Issuer)
- INSIDERAmendment: SEC Form 4/A filed by CDT Equity Inc.4/A - CDT Equity Inc. (0001896212) (Issuer)
- INSIDERSEC Form 3 filed by CDT Equity Inc.3 - CDT Equity Inc. (0001896212) (Issuer)
- SECSEC Form 8-K filed by CDT Equity Inc.8-K - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of LaunchNAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into an evaluation agreement with Manoira Corporation ("Manoira"), a specialty animal health company, to assess the potential of CDT's clinical-stage assets AZD1656, including certain proprietary cocrystal derivatives, and AZD5904 to enhance Manoira's forthcoming animal health products. Manoira is preparing to launch its first range of animal health products in the first quarter of 2027, built on its licensed portfolio of patented cannabinoid cocrystal and solid-form technologies. Manoira believes these products offer a co
- SECSEC Form PRE 14A filed by CDT Equity Inc.PRE 14A - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory AssetNAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually. "Sarborg has now built a valuable portfolio of patented solid-form assets, and this filing strengthens its asset base and its prospects as it builds a data package to support licensing and partnership discussions," said James Bligh, Chief Executive Officer of CDT. "As a significant shareholder in Sarborg, CDT is enc
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form 8-K filed by CDT Equity Inc.8-K - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug DiscoveryNAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million. A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news. Sarborg Expands Quantum Computing Patent Portfolio, Applying Quantum Sampling to Disease Biology and Drug
- SECCDT Equity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Equity Inc. Announces Reverse Stock SplitNAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on Th
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- SECCDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and VitiligoNAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases. CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible for clinical success. Initial studies will be centred around ta
CDT FAQ
8 questionsWhat is the latest news on CDT?
In the last 30 days Quantisnow tracked 17 wire items for CDT: 10 SEC filings, 3 press releases and news items, 3 insider trades and 1 13D/G filing. The most recent was published on November 9, 2026.Is CDT profitable?
No. CDT Equity Inc. reported a net loss of $37.15M for the twelve months ended Jun 30, 2026.How much cash and debt does CDT have?
CDT Equity Inc. reported $747.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CDT stock trade?
CDT Equity Inc. (CDT) is listed on NASDAQ.What sector and industry is CDT in?
CDT Equity Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CDT Equity Inc. go public?
CDT Equity Inc. (CDT) completed its IPO in 2022.What companies are similar to CDT?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare CDT side-by-side with any of them on Quantisnow.How can I track CDT on Quantisnow?
Quantisnow aggregates CDT Equity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDT to receive live email and push alerts on every new disclosure.